Sign up to save your podcasts
Or
Share 273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.
View all episodes
By STAT
4.5
303303 ratings
Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.
More shows like The Readout Loud
View all
Planet Money
30,951 Listeners
a16z Podcast
1,019 Listeners
Odd Lots
1,780 Listeners
How I Built This with Guy Raz
30,243 Listeners
The Daily
111,155 Listeners
KFF Health News' 'What the Health?'
482 Listeners
The Long Run with Luke Timmerman
123 Listeners
Tradeoffs
385 Listeners
Biotech 2050 Podcast
60 Listeners
Business Of Biotech
87 Listeners
BioCentury This Week
30 Listeners
Raising Health
146 Listeners
Biotech Hangout
10 Listeners
Ground Truths
44 Listeners
Money Stuff: The Podcast
364 Listeners